- Home
- SLN vs MREO Comparison
SLN vs MREO Comparison
Compare SLN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- MREO
- Stock Information
- Founded
- SLN 1994
- MREO 2015
- Country
- SLN United Kingdom
- MREO United Kingdom
- Employees
- SLN N/A
- MREO N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SLN Health Care
- MREO Health Care
- Exchange
- SLN Nasdaq
- MREO Nasdaq
- Market Cap
- SLN 345.3M
- MREO 286.4M
- IPO Year
- SLN N/A
- MREO N/A
- Fundamental
- Price
- SLN $6.67
- MREO $1.85
- Analyst Decision
- SLN Buy
- MREO Strong Buy
- Analyst Count
- SLN 6
- MREO 5
- Target Price
- SLN $39.67
- MREO $7.40
- AVG Volume (30 Days)
- SLN 212.8K
- MREO 1.3M
- Earning Date
- SLN 11-06-2025
- MREO 11-10-2025
- Dividend Yield
- SLN N/A
- MREO N/A
- EPS Growth
- SLN N/A
- MREO N/A
- EPS
- SLN N/A
- MREO N/A
- Revenue
- SLN $25,830,000.00
- MREO $500,000.00
- Revenue This Year
- SLN N/A
- MREO N/A
- Revenue Next Year
- SLN N/A
- MREO $72.16
- P/E Ratio
- SLN N/A
- MREO N/A
- Revenue Growth
- SLN 40.39
- MREO N/A
- 52 Week Low
- SLN $1.97
- MREO $1.47
- 52 Week High
- SLN $8.88
- MREO $3.94
- Technical
- Relative Strength Index (RSI)
- SLN 55.39
- MREO 49.16
- Support Level
- SLN $5.91
- MREO $1.75
- Resistance Level
- SLN $6.62
- MREO $1.87
- Average True Range (ATR)
- SLN 0.51
- MREO 0.11
- MACD
- SLN -0.05
- MREO 0.00
- Stochastic Oscillator
- SLN 81.25
- MREO 67.86
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).